CY1115999T1 - Νεα και ισχυρα mhc- κατηγοριας ιι πεπτιδια που προερχονται απο σουρβιβινη και νευροκανη - Google Patents
Νεα και ισχυρα mhc- κατηγοριας ιι πεπτιδια που προερχονται απο σουρβιβινη και νευροκανηInfo
- Publication number
- CY1115999T1 CY1115999T1 CY20151100138T CY151100138T CY1115999T1 CY 1115999 T1 CY1115999 T1 CY 1115999T1 CY 20151100138 T CY20151100138 T CY 20151100138T CY 151100138 T CY151100138 T CY 151100138T CY 1115999 T1 CY1115999 T1 CY 1115999T1
- Authority
- CY
- Cyprus
- Prior art keywords
- present
- surbivin
- neurocane
- category
- purposes
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/10—Peptides having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001148—Regulators of development
- A61K39/00115—Apoptosis related proteins, e.g. survivin or livin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4747—Apoptosis related proteins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/7056—Lectin superfamily, e.g. CD23, CD72
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Hematology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP08008944.4A EP2119726B2 (en) | 2008-05-14 | 2008-05-14 | Novel and powerful MHC-class II peptides derived from survivin and neurocan |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CY1115999T1 true CY1115999T1 (el) | 2017-01-25 |
Family
ID=39789337
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CY20151100138T CY1115999T1 (el) | 2008-05-14 | 2015-02-12 | Νεα και ισχυρα mhc- κατηγοριας ιι πεπτιδια που προερχονται απο σουρβιβινη και νευροκανη |
| CY20151100921T CY1117171T1 (el) | 2008-05-14 | 2015-10-14 | Καινοτομα και ισχυρα πεπτιδια mch tαξης ιι προερχομενα απο την σουρβιβινη |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CY20151100921T CY1117171T1 (el) | 2008-05-14 | 2015-10-14 | Καινοτομα και ισχυρα πεπτιδια mch tαξης ιι προερχομενα απο την σουρβιβινη |
Country Status (24)
| Country | Link |
|---|---|
| US (5) | US8647629B2 (forum.php) |
| EP (3) | EP2119726B2 (forum.php) |
| JP (1) | JP5663473B2 (forum.php) |
| KR (2) | KR101509284B1 (forum.php) |
| CN (1) | CN102027006B (forum.php) |
| AU (1) | AU2009248413B2 (forum.php) |
| BR (2) | BR122019014468B8 (forum.php) |
| CA (1) | CA2724198C (forum.php) |
| CY (2) | CY1115999T1 (forum.php) |
| DK (2) | DK2119726T5 (forum.php) |
| EA (1) | EA019603B1 (forum.php) |
| ES (2) | ES2532896T5 (forum.php) |
| HK (1) | HK1209757A1 (forum.php) |
| HR (2) | HRP20151135T4 (forum.php) |
| HU (2) | HUE024541T2 (forum.php) |
| MX (1) | MX2010012443A (forum.php) |
| NO (1) | NO2119726T3 (forum.php) |
| NZ (1) | NZ588605A (forum.php) |
| PL (2) | PL2119726T5 (forum.php) |
| PT (2) | PT2119726E (forum.php) |
| RS (1) | RS53872B2 (forum.php) |
| SI (2) | SI2119726T2 (forum.php) |
| UA (1) | UA103481C2 (forum.php) |
| WO (1) | WO2009138236A1 (forum.php) |
Families Citing this family (68)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2012079878A2 (en) * | 2010-12-14 | 2012-06-21 | Immatics Biotechnologies Gmbh | Hla-binding peptides derived from prostate-associated antigenic molecules and methods of use thereof |
| US8435507B2 (en) | 2004-08-19 | 2013-05-07 | University Of Maryland | Prostate-specific antigen-derived MHC class II restricted peptides and their use in vaccines to treat or prevent prostate cancer |
| ES2608583T3 (es) * | 2007-07-27 | 2017-04-12 | Immatics Biotechnologies Gmbh | Composición de péptidos asociados a tumor y vacuna antitumoral relacionada |
| CN102014965B (zh) | 2008-04-29 | 2015-11-25 | 阿森迪斯药物生长障碍股份有限公司 | Peg化的重组人生长激素化合物 |
| PL2113253T3 (pl) * | 2008-04-30 | 2010-09-30 | Immatics Biotechnologies Gmbh | Nowa postać leku - preparat zawierający peptydy nowotworowe wiążące się z antygenami ludzkich leukocytów klasy I i II, zastosowany w szczepionce |
| SI2119726T2 (en) | 2008-05-14 | 2018-03-30 | Immatics Biotechnologies Gmbh | New and powerful Class II MHC peptides derived from survivin and neurocane |
| MX337432B (es) * | 2009-12-15 | 2016-03-04 | Ascendis Pharma As | Composicion de la hormona del crecimiento seca enlazada transitoriamente a un portador del polimero. |
| FR2955112B1 (fr) | 2010-01-14 | 2012-01-20 | Isp Investments Inc | Nouveaux peptides anti-age modulateurs de la survivine et compositions les comprenant |
| GB201004575D0 (en) * | 2010-03-19 | 2010-05-05 | Immatics Biotechnologies Gmbh | Composition of tumor associated peptides and related anti cancer vaccine for the treatment of gastric cancer and other cancers |
| GB201009222D0 (en) * | 2010-06-02 | 2010-07-21 | Immatics Biotechnologies Gmbh | Improved cancer therapy based on tumour associated antigens derived from cyclin D1 |
| WO2012023033A2 (en) | 2010-08-18 | 2012-02-23 | Purdue Pharma L.P. | Improved peptide immunogens |
| CN102181401B (zh) * | 2011-02-01 | 2013-04-24 | 北京市肿瘤防治研究所 | 存活素酶联免疫试剂盒及其应用 |
| JP6512568B2 (ja) * | 2013-02-05 | 2019-05-15 | 日東電工株式会社 | 経皮投与用ｗｔ１ペプチド癌ワクチン組成物 |
| DE102013012432A1 (de) * | 2013-07-29 | 2015-01-29 | Eberhard Karls Universität Tübingen Medizinische Fakultät | Immuntherapie von Prostatakrebs |
| WO2015066057A2 (en) * | 2013-10-28 | 2015-05-07 | Baylor College Of Medicine | Expansion of cmv-specific t cells from cmv-seronegative donors |
| GB201319446D0 (en) | 2013-11-04 | 2013-12-18 | Immatics Biotechnologies Gmbh | Personalized immunotherapy against several neuronal and brain tumors |
| GB201321242D0 (en) * | 2013-12-02 | 2014-01-15 | Immune Targeting Systems Its Ltd | Immunogenic compound |
| PT3653227T (pt) | 2014-11-18 | 2021-02-26 | Ascendis Pharma Endocrinology Div A/S | Novos pró-fármacos poliméricos de hgh |
| DK3220892T3 (da) | 2014-11-21 | 2021-11-08 | Ascendis Pharma Endocrinology Div A/S | Langtidsvirkende væksthormondoseringsformer |
| US20180133327A1 (en) | 2015-03-16 | 2018-05-17 | Amal Therapeutics Sa | Cell Penetrating Peptides and Complexes Comprising the Same |
| GB201504502D0 (en) * | 2015-03-17 | 2015-04-29 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides for use in immunotherapy against pancreatic cancer and other cancers |
| GB201505305D0 (en) | 2015-03-27 | 2015-05-13 | Immatics Biotechnologies Gmbh | Novel Peptides and combination of peptides for use in immunotherapy against various tumors |
| MY193703A (en) * | 2015-03-27 | 2022-10-26 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides for use in immunotherapy against various tumors |
| NL2014935B1 (en) | 2015-06-08 | 2017-02-03 | Applied Immune Tech Ltd | T cell receptor like antibodies having fine specificity. |
| HRP20202019T1 (hr) * | 2015-07-01 | 2021-04-30 | Immatics Biotechnologies Gmbh | Novi peptidi i kombinacija peptida za uporabu u imunoterapiji protiv raka jajnika i drugih malignih tumora |
| MX2017017148A (es) * | 2015-07-06 | 2018-02-23 | Immatics Biotechnologies Gmbh | Peptidos novedosos y combinacion de peptidos para usarse en la inmunoterapia contra cancer esofagico y otros canceres. |
| MY189596A (en) * | 2015-07-15 | 2022-02-18 | Immatics Biotechnologies Gmbh | A novel peptides for use in immunotherapy against epithelial ovarian cancer and other cancers |
| GB201513921D0 (en) | 2015-08-05 | 2015-09-23 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides for use in immunotherapy against prostate cancer and other cancers |
| HK1258386A1 (zh) * | 2015-10-05 | 2019-11-08 | Immatics Biotechnologies Gmbh | 用於小细胞肺癌和其他癌症免疫治疗的肽和肽组合物 |
| GB201521746D0 (en) * | 2015-12-10 | 2016-01-27 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides for use in immunotherapy against CLL and other cancers |
| HK1255541A1 (zh) * | 2015-12-11 | 2019-08-23 | Immatics Biotechnologies Gmbh | 用於多种癌症免疫治疗的新型肽和肽组合物 |
| BR112018012374A2 (pt) | 2015-12-16 | 2018-12-04 | Gritstone Oncology, Inc. | identificação, fabricação e uso de neoantígeno |
| GB201522667D0 (en) | 2015-12-22 | 2016-02-03 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides for use in immunotherapy against breast cancer and other cancers |
| HRP20210698T1 (hr) | 2015-12-22 | 2021-09-17 | Immatics Biotechnologies Gmbh | Peptidi i kombinacija peptida za uporabu u imunoterapiji protiv karcinoma dojke i drugih karcinoma |
| DK3429618T5 (da) | 2016-03-16 | 2024-09-16 | Amal Therapeutics Sa | Kombination af en immuncheckpoint-modulator og et kompleks som omfatter et cellepenetrerende peptid, en last og en tlr-peptidagonist til anvendelse i medicin |
| GB201604458D0 (en) * | 2016-03-16 | 2016-04-27 | Immatics Biotechnologies Gmbh | Peptides and combination of peptides for use in immunotherapy against cancers |
| GB201604755D0 (en) * | 2016-03-21 | 2016-05-04 | Vaxeal Res Sas | Immunogenic compositions |
| GB201609193D0 (en) * | 2016-05-25 | 2016-07-06 | Immatics Biotechnologies Gmbh | Novel peptides, combination of peptides as targets for use in immunotherapy against gallbladder cancer and cholangiocarcinoma and other cancers |
| MA45491A (fr) * | 2016-06-27 | 2019-05-01 | Juno Therapeutics Inc | Épitopes à restriction cmh-e, molécules de liaison et procédés et utilisations associés |
| AU2017290119A1 (en) * | 2016-06-28 | 2019-01-24 | Geneius Biotechnology, Inc. | T cell compositions for immunotherapy |
| DK3515476T3 (da) | 2016-09-21 | 2024-09-02 | Amal Therapeutics Sa | Fusion der omfatter et cellepenetrerende peptid, en multiepitop og en trl-peptidagnost til behandlingen af cancer |
| DE102016123893A1 (de) | 2016-12-08 | 2018-06-14 | Immatics Biotechnologies Gmbh | T-Zellrezeptoren mit verbesserter Bindung |
| KR102639592B1 (ko) | 2016-12-08 | 2024-02-21 | 이매틱스 바이오테크놀로지스 게엠베하 | 짝짓기가 향상된 t 세포 수용체 |
| BR112019015237A2 (pt) | 2017-01-27 | 2020-04-14 | Immatics Biotechnologies Gmbh | peptídeos e combinações de peptídeos para uso em imunoterapia contra câncer de ovário e outros cânceres |
| AR110857A1 (es) | 2017-01-27 | 2019-05-08 | Immatics Biotechnologies Gmbh | Péptidos y combinaciones de péptidos para el uso en la inmunoterapia contra el cáncer de ovario y otros tipos de cáncer |
| BR112019018307A2 (pt) | 2017-03-03 | 2020-03-31 | Treos Bio Zrt | Plataforma para identificação de peptídeos imunogênicos baseada em população |
| CR20210169A (es) | 2017-07-07 | 2021-06-10 | Immatics Biotechnologies Gmbh | NUEVOS PÉPTIDOS Y NUEVAS COMBINACIONES DE PÉPTIDOS PARA EL USO DE LA INMUNOTERAPIA CONTRA EL CÁNCER DE PULMÓN, INCLUYENDO EL NSCLC, EL SCLC Y OTROS CÁNCERES (Divisional 2020-0059) |
| US10800823B2 (en) * | 2017-07-07 | 2020-10-13 | Immatics Biotechnologies Gmbh | Peptides and combination of peptides for use in immunotherapy against lung cancer, including NSCLC, SCLC and other cancers |
| EP3694541A2 (en) | 2017-10-09 | 2020-08-19 | Enterome S.A. | Microbiota sequence variants of tumor-related antigenic epitopes |
| JP7227237B2 (ja) | 2017-10-10 | 2023-02-21 | グリットストーン バイオ インコーポレイテッド | ホットスポットを利用した新生抗原の特定 |
| WO2019089755A1 (en) | 2017-10-31 | 2019-05-09 | Western Oncolytics Ltd. | Platform oncolytic vector for systemic delivery |
| CN111630602A (zh) | 2017-11-22 | 2020-09-04 | 磨石肿瘤生物技术公司 | 减少新抗原的接合表位呈递 |
| DE102018107224A1 (de) * | 2018-02-21 | 2019-08-22 | Immatics Biotechnologies Gmbh | Peptide und Kombinationen von Peptiden nicht-kanonischen Ursprungs zur Verwendung in der Immuntherapie gegen verschiedene Krebsarten |
| US20210106652A1 (en) | 2018-04-11 | 2021-04-15 | Enterome S.A. | Immunogenic Compounds For Treatment Of Fibrosis, Autoimmune Diseases And Inflammation |
| WO2019197567A2 (en) | 2018-04-11 | 2019-10-17 | Enterome S.A. | Antigenic peptides for prevention and treatment of cancer |
| EP3794014A4 (en) * | 2018-05-15 | 2022-03-16 | InterK Peptide Therapeutics Limited | PEPTIDE ENHANCING AGENT |
| AU2019268411B2 (en) * | 2018-05-15 | 2024-03-14 | Interk Peptide Therapeutics Limited | Activating agents |
| MA53543A (fr) | 2018-09-04 | 2021-07-14 | Treos Bio Ltd | Vaccins peptidiques |
| AU2020233198B2 (en) | 2019-03-04 | 2025-05-15 | Ascendis Pharma Endocrinology Division A/S | Long-acting growth hormone dosage forms with superior efficacy to daily somatropin |
| EP4045150A1 (en) | 2019-10-16 | 2022-08-24 | Enterome S.A. | Immunogenic compounds for treatment of adrenal cancer |
| LT4021487T (lt) | 2019-11-15 | 2024-02-12 | Enterome S.A. | Antigeniniai peptidai, skirti b-ląstelių piktybinių navikų prevencijai ir gydymui |
| CN113045635A (zh) * | 2019-12-26 | 2021-06-29 | 上海细胞治疗集团有限公司 | 一种特异性结合hla-a2分型的多肽组合物及应用 |
| JP2023521219A (ja) * | 2020-04-14 | 2023-05-23 | ウニヴェルシテ ド モントリオール | 急性骨髄性白血病（ａｍｌ）に対する新規の腫瘍特異的抗原及びそれらの使用 |
| CA3197371A1 (en) | 2020-11-19 | 2022-05-27 | Kalivir Immunotherapeutics, Inc. | Oncolytic immunotherapy by tumor micro-environment remodeling |
| JP7661734B2 (ja) * | 2021-03-19 | 2025-04-15 | 日本電気株式会社 | 検査システム及び検査方法 |
| PE20250454A1 (es) * | 2021-04-30 | 2025-02-19 | Kalivir Immunotherapeutics Inc | Virus oncoliticos para la expresion modificada del mhc |
| WO2023021056A1 (en) * | 2021-08-17 | 2023-02-23 | Intomics A/S | Vaccine design pipeline |
| JP2025511086A (ja) | 2022-03-31 | 2025-04-15 | アンテローム・エス・ア | 癌の防止及び処置のための抗原性ペプチド |
Family Cites Families (46)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4440859A (en) | 1977-05-27 | 1984-04-03 | The Regents Of The University Of California | Method for producing recombinant bacterial plasmids containing the coding sequences of higher organisms |
| US4704362A (en) | 1977-11-08 | 1987-11-03 | Genentech, Inc. | Recombinant cloning vehicle microbial polypeptide expression |
| YU44186B (en) | 1978-12-22 | 1990-04-30 | Biogen Nv | Process for obtaining recombinant dnk molecules |
| US4530901A (en) | 1980-01-08 | 1985-07-23 | Biogen N.V. | Recombinant DNA molecules and their use in producing human interferon-like polypeptides |
| US4342566A (en) | 1980-02-22 | 1982-08-03 | Scripps Clinic & Research Foundation | Solid phase anti-C3 assay for detection of immune complexes |
| US4678751A (en) | 1981-09-25 | 1987-07-07 | Genentech, Inc. | Hybrid human leukocyte interferons |
| US4766075A (en) | 1982-07-14 | 1988-08-23 | Genentech, Inc. | Human tissue plasminogen activator |
| US4582800A (en) | 1982-07-12 | 1986-04-15 | Hoffmann-La Roche Inc. | Novel vectors and method for controlling interferon expression |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US4757006A (en) | 1983-10-28 | 1988-07-12 | Genetics Institute, Inc. | Human factor VIII:C gene and recombinant methods for production |
| US4677063A (en) | 1985-05-02 | 1987-06-30 | Cetus Corporation | Human tumor necrosis factor |
| US4810648A (en) | 1986-01-08 | 1989-03-07 | Rhone Poulenc Agrochimie | Haloarylnitrile degrading gene, its use, and cells containing the gene |
| US4772547A (en) * | 1986-02-03 | 1988-09-20 | Hoffmann-La Roche Inc. | HTLV-III envelope peptides |
| US4897445A (en) | 1986-06-27 | 1990-01-30 | The Administrators Of The Tulane Educational Fund | Method for synthesizing a peptide containing a non-peptide bond |
| US5057540A (en) * | 1987-05-29 | 1991-10-15 | Cambridge Biotech Corporation | Saponin adjuvant |
| US5733742A (en) | 1993-06-03 | 1998-03-31 | Therapeutic Antibodies Inc. | Production of antibody fragments from whole blood |
| AUPM322393A0 (en) | 1993-12-24 | 1994-01-27 | Austin Research Institute, The | Mucin carbohydrate compounds and their use in immunotherapy |
| DK0879282T3 (da) | 1996-01-17 | 2003-10-20 | Imp College Innovations Ltd | Immunterapi ved anvendelse af cytotoksiske T-lymfocytter (CTL) |
| US5849589A (en) | 1996-03-11 | 1998-12-15 | Duke University | Culturing monocytes with IL-4, TNF-α and GM-CSF TO induce differentiation to dendric cells |
| US6406705B1 (en) | 1997-03-10 | 2002-06-18 | University Of Iowa Research Foundation | Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant |
| US6420518B1 (en) * | 1997-04-04 | 2002-07-16 | Genetech, Inc. | Insulin-like growth factor agonist molecules |
| US6255055B1 (en) * | 1998-03-09 | 2001-07-03 | Wisconsin Alumni Research Foundation | c-myc coding region determinant-binding protein (CRD-BP) and its nucleic acid sequence |
| US6274362B1 (en) * | 1999-02-04 | 2001-08-14 | Millennium Pharmaceuticals, Inc. | RGS-containing molecules and uses thereof |
| AU785493B2 (en) | 2000-03-27 | 2008-01-03 | Technion Research & Development Foundation Ltd. | Single chain class I major histo-compatibility complexes, constructs encoding same and methods of generating same |
| US20040191260A1 (en) | 2003-03-26 | 2004-09-30 | Technion Research & Development Foundation Ltd. | Compositions capable of specifically binding particular human antigen presenting molecule/pathogen-derived antigen complexes and uses thereof |
| EP1300418A1 (en) * | 2001-10-04 | 2003-04-09 | Erasmus Universiteit Rotterdam | Gene regulation by oligopeptides |
| WO2003042661A2 (en) * | 2001-11-13 | 2003-05-22 | Protein Design Labs, Inc. | Methods of diagnosis of cancer, compositions and methods of screening for modulators of cancer |
| WO2003051051A1 (en) | 2001-12-13 | 2003-06-19 | Koninklijke Philips Electronics N.V. | Recommending media content on a media system |
| US7892559B2 (en) * | 2002-01-30 | 2011-02-22 | Survac Aps | Survivin-derived peptides and use thereof |
| US6992176B2 (en) | 2002-02-13 | 2006-01-31 | Technion Research & Development Foundation Ltd. | Antibody having a T-cell receptor-like specificity, yet higher affinity, and the use of same in the detection and treatment of cancer, viral infection and autoimmune disease |
| JP2005533486A (ja) | 2002-02-20 | 2005-11-10 | ダイアックス、コープ | Ｍｈｃ−ペプチド複合体結合リガンド |
| DE10225144A1 (de) * | 2002-05-29 | 2003-12-18 | Immatics Biotechnologies Gmbh | An MHC-Moleküle bindende Tumor-assoziierte Peptide |
| CA2496888A1 (en) * | 2002-09-06 | 2004-03-18 | Mannkind Corporation | Epitope sequences |
| US7468254B2 (en) * | 2003-01-21 | 2008-12-23 | Arius Research Inc. | Cytotoxicity mediation of cells evidencing surface expression of MCSP |
| US7811828B2 (en) * | 2004-01-28 | 2010-10-12 | Immatics Biotechnologies Gmbh | Method for identifying and quantifying of tumuor-associated |
| DE102004026135A1 (de) * | 2004-05-25 | 2006-01-05 | Immatics Biotechnologies Gmbh | An MHC-Moleküle bindende Tumor-assoziierte Peptide |
| US8435507B2 (en) * | 2004-08-19 | 2013-05-07 | University Of Maryland | Prostate-specific antigen-derived MHC class II restricted peptides and their use in vaccines to treat or prevent prostate cancer |
| ES2330013T3 (es) | 2005-09-05 | 2009-12-03 | Immatics Biotechnologies Gmbh | Peptidos asociados a tumores unidos a moleculas del antigeno de leucocito humano (hla) de clase i o ii y vacunas contra el cancer relacionadas. |
| PL1806359T3 (pl) | 2005-09-05 | 2010-08-31 | Immatics Biotechnologies Gmbh | Peptydy towarzyszące nowotworom, wiążące się swobodnie z cząsteczkami ludzkich antygenów leukocytarnych (HLA) klasy II |
| US20070104689A1 (en) * | 2005-09-27 | 2007-05-10 | Merck Patent Gmbh | Compositions and methods for treating tumors presenting survivin antigens |
| FR2891462B1 (fr) * | 2005-09-30 | 2009-10-16 | Commissariat Energie Atomique | Epitopes t cd4+ de la survivine et leurs applications |
| WO2007056511A2 (en) † | 2005-11-09 | 2007-05-18 | Ontherix, Inc. | Metal-binding therapeutic peptides |
| ES2608583T3 (es) * | 2007-07-27 | 2017-04-12 | Immatics Biotechnologies Gmbh | Composición de péptidos asociados a tumor y vacuna antitumoral relacionada |
| PL2113253T3 (pl) * | 2008-04-30 | 2010-09-30 | Immatics Biotechnologies Gmbh | Nowa postać leku - preparat zawierający peptydy nowotworowe wiążące się z antygenami ludzkich leukocytów klasy I i II, zastosowany w szczepionce |
| SI2119726T2 (en) * | 2008-05-14 | 2018-03-30 | Immatics Biotechnologies Gmbh | New and powerful Class II MHC peptides derived from survivin and neurocane |
| ES2536465T3 (es) * | 2008-10-01 | 2015-05-25 | Immatics Biotechnologies Gmbh | Composición de péptidos tumor-asociados y relacionados con la vacuna contra el cáncer para el tratamiento de glioblastoma (GBM) y otros cánceres |
-
2008
- 2008-05-14 SI SI200831406T patent/SI2119726T2/en unknown
- 2008-05-14 NO NO08008944A patent/NO2119726T3/no unknown
- 2008-05-14 DK DK08008944.4T patent/DK2119726T5/en active
- 2008-05-14 RS RS20150093A patent/RS53872B2/sr unknown
- 2008-05-14 PL PL08008944T patent/PL2119726T5/pl unknown
- 2008-05-14 ES ES08008944.4T patent/ES2532896T5/es active Active
- 2008-05-14 PT PT08008944T patent/PT2119726E/pt unknown
- 2008-05-14 HU HUE08008944A patent/HUE024541T2/hu unknown
- 2008-05-14 EP EP08008944.4A patent/EP2119726B2/en active Active
-
2009
- 2009-05-14 CA CA2724198A patent/CA2724198C/en not_active Expired - Fee Related
- 2009-05-14 MX MX2010012443A patent/MX2010012443A/es active IP Right Grant
- 2009-05-14 JP JP2011508840A patent/JP5663473B2/ja not_active Expired - Fee Related
- 2009-05-14 HR HRP20151135TT patent/HRP20151135T4/hr unknown
- 2009-05-14 EA EA201071297A patent/EA019603B1/ru not_active IP Right Cessation
- 2009-05-14 EP EP15154297.4A patent/EP2899206A1/en not_active Withdrawn
- 2009-05-14 EP EP09745570.3A patent/EP2291395B2/en active Active
- 2009-05-14 CN CN200980117564.0A patent/CN102027006B/zh not_active Expired - Fee Related
- 2009-05-14 BR BR122019014468A patent/BR122019014468B8/pt not_active IP Right Cessation
- 2009-05-14 AU AU2009248413A patent/AU2009248413B2/en not_active Ceased
- 2009-05-14 ES ES09745570T patent/ES2549088T5/es active Active
- 2009-05-14 DK DK09745570.3T patent/DK2291395T4/en active
- 2009-05-14 KR KR1020107027934A patent/KR101509284B1/ko not_active Expired - Fee Related
- 2009-05-14 HU HUE09745570A patent/HUE028102T2/en unknown
- 2009-05-14 KR KR1020137008071A patent/KR101602024B1/ko not_active Expired - Fee Related
- 2009-05-14 UA UAA201015020A patent/UA103481C2/ru unknown
- 2009-05-14 US US12/466,222 patent/US8647629B2/en active Active
- 2009-05-14 SI SI200931275T patent/SI2291395T2/sl unknown
- 2009-05-14 WO PCT/EP2009/003447 patent/WO2009138236A1/en active Application Filing
- 2009-05-14 BR BRPI0912622A patent/BRPI0912622A2/pt not_active Application Discontinuation
- 2009-05-14 PL PL09745570T patent/PL2291395T5/pl unknown
- 2009-05-14 PT PT97455703T patent/PT2291395E/pt unknown
- 2009-05-14 NZ NZ588605A patent/NZ588605A/en not_active IP Right Cessation
-
2011
- 2011-06-03 HK HK15110277.6A patent/HK1209757A1/en unknown
-
2012
- 2012-06-19 US US13/526,597 patent/US9498512B2/en active Active
-
2013
- 2013-03-15 US US13/841,442 patent/US20140086943A1/en not_active Abandoned
- 2013-06-28 US US13/931,413 patent/US10434136B2/en active Active
-
2015
- 2015-02-12 CY CY20151100138T patent/CY1115999T1/el unknown
- 2015-03-17 HR HRP20150300TT patent/HRP20150300T4/hr unknown
- 2015-10-14 CY CY20151100921T patent/CY1117171T1/el unknown
-
2019
- 2019-07-12 US US16/510,442 patent/US11957729B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1115999T1 (el) | Νεα και ισχυρα mhc- κατηγοριας ιι πεπτιδια που προερχονται απο σουρβιβινη και νευροκανη | |
| CY1119739T1 (el) | Καινοτομος ανοσοθεραπεια εναντι ογκων του εγκεφαλου | |
| CY1119744T1 (el) | Μια συνθεση που αποτελειται απο ογκο-σχετιζομενα πεπτιδια και ενα εμβολιο για την θεραπεια του γλοιοβλαστωματος και αλλων καρκινων | |
| CY1117115T1 (el) | Καινοτομος ανοσοθεραπεια εναντι ογκων και νευρωνων του εγκεφαλου | |
| CY1121691T1 (el) | Εξατομικευμενη ανοσοθεραπεια εναντι ογκων των νευρωνων και του εγκεφαλου | |
| CY1124950T1 (el) | Καινοτομος ανοσοθεραπεια εναντι διαφορων ογκων, οπως του καρκινου του πνευμονα συμπεριλαμβανομενου του μμκπ | |
| CY1123854T1 (el) | Πεπτιδια και συνδυασμος πεπτιδιων για χρηση στην ανοσοθεραπεια εναντι του καρκινου του προστατη και αλλων καρκινων | |
| CY1123635T1 (el) | Καινοτομα πεπτιδια και συνδυασμος πεπτιδιων για χρηση στην ανοσοθεραπεια εναντι του καρκινου των ωοθηκων και αλλων καρκινων | |
| CY1123505T1 (el) | Καινοτομα πεπτιδια και συνδυασμος πεπτιδιων για χρηση στην ανοσοθεραπεια εναντι του επιθηλιακου καρκινου των ωοθηκων και αλλων καρκινων | |
| CY1124224T1 (el) | Πεπτιδια και συνδυασμος πεπτιδιων για χρηση στην ανοσοθεραπεια κατα του καρκινου του μαστου και αλλων καρκινων | |
| CY1119219T1 (el) | Anti-ceacam5 αντισωματα και χρησεις αυτων | |
| EA201891638A1 (ru) | Новые пептиды и комбинации пептидов для применения в иммунотерапии нхл и других видов рака | |
| EA201792484A1 (ru) | Новые клеточные эпитопы и комбинации клеточных эпитопов для применения в иммунотерапии миеломы и других видов рака | |
| EA201792632A1 (ru) | Новые пептиды и комбинации пептидов для применения в иммунотерапии рака яичника и других видов рака | |
| EA201791150A1 (ru) | Новые пептиды и комбинации пептидов для применения в иммунотерапии гепатоклеточной карциномы (гкк) и других видов рака | |
| CY1110178T1 (el) | Νεα σκευασματα πεπτιδιων που σχετιζονται με ογκους τα οποια συνδεονται σε μορια του αντιγονου ανθρωπινων λευκοκυτταρων (hla) ταξης ι ή ιι για εμβολια | |
| CY1107973T1 (el) | Σχετιζομενα με ογκους πεπτιδια, που συνδεονται ετεροκλητως με μορια κλασεως ιι αντιγονου ανθρωπινων λευκοκυτταρων | |
| MX2011011132A (es) | Peptido auxiliar del antigeno del cancer. | |
| CY1124038T1 (el) | Καινοτομα πεπτιδια και συνδυασμος πεπτιδιων και ικριωματων αυτων για χρηση στην ανοσοθεραπεια εναντι του ορθοκολικου καρκινου (crc) και αλλων καρκινων | |
| CY1124533T1 (el) | Καινοτομα πεπτιδια και συνδυασμος πεπτιδιων για χρηση στην ανοσοθεραπεια εναντι του ηπατοκυτταρικου καρκινωματος (hcc) και αλλων καρκινων | |
| CY1122083T1 (el) | Καινοτομος ανοσοθεραπεια εναντι ορισμενων ογκων του αιματος, οπως της οξειας μυελογεους λευχαιμιας (ομλ) | |
| CY1119253T1 (el) | Καινοτομος ανοσοθεραπεια εναντι ογκων και νευρωνων του εγκεφαλου | |
| CY1116819T1 (el) | Καινοτομος ανοσοθεραπεια εναντι διαφορων ογκων συμπεριλαμβανομενου του γαστρεντερικου και γαστρικου καρκινου |